Neuronetics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Neuronetics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Goodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative. Less tangible than 93% of Healthcare companies in United States.
- Cash Cushion Ratio: Debt, after subtracting cash, equals 39% of its market value (net debt). Lower than 90% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-18.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 57% of Healthcare companies in United States.
Cash Locked Ratio
$6For every $100 of sales, $6 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $30 tied up three years earlier.
Less money tied up than 85% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
−$2Sales grew 129% in 3 years, but profit fell: $2 less profit per $100 of extra sales.
Lower than 70% of Healthcare companies in United States.
Asset Productivity Ratio
+129% / +21%In 3 years sales changed by +129% while total assets changed by +21%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-3.7×Operating cash was negative last year, while some debt falls due within a year.
Higher than 61% of Healthcare companies in United States.
Cash Cushion Ratio
−39%Debt, after subtracting cash, equals 39% of its market value (net debt).
Lower than 90% of Healthcare companies in United States.
Tangible Assets Ratio
70%Of every $100 the company owns, $70 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 61% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 93% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Neuronetics, Inc. made a loss over the last year. Neuronetics, Inc. owes $0.84 for every $1 it owns. Neuronetics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossNeuronetics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
8.88The share price is 8.88 times Neuronetics, Inc.'s book value per share, higher than 85% of Healthcare companies in United States.
Market cap
$158 MThe total market value of all of Neuronetics, Inc.'s shares at today's price (share price × number of shares), smaller than 60% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$18 MWhat Neuronetics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.23Net worth divided by the number of shares. The share price of $2.08 is 8.9 times this, which is the P/B above.
Return on equity (ROE)
-116.1%Neuronetics, Inc. lost 116.1% of its shareholders' money over the last year, lower than 75% of Healthcare companies in United States.
Owes vs Owns
0.84×Neuronetics, Inc. owes $0.84 for every $1 it owns (high), higher than 80% of Healthcare companies in United States.
Dividend yield
NoneNeuronetics, Inc. does not currently pay a dividend.
Revenue growth
+99%Revenue rose 99% in the year to Dec 2025, and grew 32% a year on average over 3 years.
Profit growth
LossNeuronetics, Inc. made a loss in each of the last two years.
Profit margin
-26.1%Neuronetics, Inc. lost $26 for every $100 of revenue.
Interest cover
Not coveredNeuronetics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtNeuronetics, Inc. had $62 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Neuronetics, Inc.: $158 M ÷ $18 M (30 Jun 2026) = 8.9.
What is Neuronetics, Inc.'s return on equity?
Neuronetics, Inc. lost 116.1% of its shareholders' money over the last year, lower than 75% of Healthcare companies in United States.
How much does Neuronetics, Inc. owe compared with what it owns?
Neuronetics, Inc. owes $0.84 for every $1 it owns (high), higher than 80% of Healthcare companies in United States.
Does Neuronetics, Inc. pay a dividend?
No. Neuronetics, Inc. does not currently pay a dividend.
Is Neuronetics, Inc.'s revenue growing?
Revenue rose 99% in the year to Dec 2025, and grew 32% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.